NovoCure (NVCR) Other Operating Expenses (2014 - 2026)

NovoCure's Other Operating Expenses history runs 13 years deep, the most recent figure standing at $58.4 million for Q1 2026.

• In Q1 2026, Other Operating Expenses rose 4.6% year-over-year to $58.4 million; the TTM figure through Mar 2026 stood at $242.6 million (up 1.24% YoY), while the FY2025 annual figure was $240.1 million, changed 0.42% from the prior year.
• Other Operating Expenses came in at $58.4 million for Q1 2026 at NovoCure, down from $68.7 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $68.7 million in Q4 2025 to a low of $37.9 million in Q1 2022.
• A 5-year average of $55.2 million and a median of $57.1 million in 2025 frame the typical range for Other Operating Expenses.
• Across the five-year window, Other Operating Expenses jumped 40.03% in 2023 and declined 3.2% in 2024, its largest moves.
• NovoCure's Other Operating Expenses stood at $49.6 million in 2022, then gained by 19.26% to $59.2 million in 2023, then climbed by 13.89% to $67.4 million in 2024, then grew by 1.85% to $68.7 million in 2025, then fell by 15.01% to $58.4 million in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $58.4 million, $68.7 million, and $58.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison